When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HEPA - Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals' (HEPA) drug, CRV431, has previously been studied in humans in Phase 1 single ascending dose clinical trial for Hepatitis B, an indication that management has deemphasized in favor of the larger NASH opportunity. In that study, the drug was found to be safe and well tolerated. CRV431 is now being investigated in a multiple ascending dose Phase 1b trial, and it was announced today that this trial will be advanced to the final dosing level of 375 mg daily for 28 days. It was also noted that steady-state concentrations achieved at